Dono et al recently reported results from a retrospective analysis that detected higher post-progression survival of 14 patients with PTEN-mutated recurrent GBs who received treatment with TTFields, compared to 15 patients with PTEN wild-type tumors (22.2 vs 11.6 months, respectively). Here, PTEN is linked to Guillain-Barre syndrome.